BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company, today announced the completed acquisition of its Founded Entity, Karuna Therapeutics, Inc. ("Karuna”), by Bristol Myers Squibb (NYSE: BMY) (“BMS”), which has acquired all outstanding common stock of Karuna for $330.00 per share, for a total equity value of approximately $14 billion. "This acquisition recognizes the enormous potential of KarXT to help millions of ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that it has successfully completed its acquisition of Karuna Therapeutics, Inc. (“Karuna”). With the acquisition's completion, Karuna shares have ceased trading on the Nasdaq Global Select Market and Karuna is now a wholly owned subsidiary of Bristol Myers Squibb (“BMS”). “We are excited to expand our neuroscience portfolio as we welcome Karuna to Bristol Myers Squibb,” said Chris Boerner, Ph.D., Chief Executive Officer, B ...

SEATTLE , March 18, 2024 (GLOBE NEWSWIRE) --  Perspective Therapeutics, Inc. (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced a clinical trial collaboration agreement with Bristol Myers Squibb (NYSE:BMY) to evaluate the safety and tolerability of Perspective's targeted alpha-particle therapy [212Pb]VMT01 in combination with Bristol Myers Squibb's nivolumab in patients with histologically confirmed melanoma and posi ...

PRINCETON, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) and 2seventy bio, Inc. (Nasdaq: TSVT) today announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted positively (8-3) that Abecma (idecabtagene vicleucel) demonstrated a favorable benefit/risk profile for patients with triple-class exposed relapsed or refractory multiple myeloma based on results from the pivotal Phase 3 KarMMa-3 study, including the key secondary endpoint o ...

Bristol Myers Squibb (BMY) announced that the FDA has granted accelerated approval to chimeric antigen receptor (CAR) T cell therapy, Breyanzi (lisocabtagene maraleucel), for one more indication.The approval was granted for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least two prior lines of therapy, including a Bruton tyrosine kinase (BTK) inhibitor and a B-cell lymphoma 2 (BCL-2) inhibitor. The acce ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Breyanzi® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least two prior lines of therapy, including a Bruton tyrosine kinase (BTK) inhibi ...

SIphotography/iStock via Getty Images Get Paid To Wait The Efficient Market Hypothesis tells us that share prices reflect all available information and therefore it is effectively impossible to consistently generate alpha. Academics have long accepted this theory and provided sufficient data to prove that it's true. While there certainly are proponents of the theory, it also has its critics. Many famous investors disagree with the hypothesis and have track records that prove it cannot be true. Regardles ...

Bristol-Myers Squibb Company (NYSE:BMY) Barclays 26th Annual Global Healthcare Conference March 14, 2024 8:30 AM ET Company Participants Lynelle Hoch - President of Cell Therapy Wendy Short Bartie - Senior Vice President, U.S. Hematology and Oncology Conference Call Participants Carter Gould - Barclays Carter Gould All right. Good morning. Welcome to the Day Three of the Barclays Global Healthcare Conference. I am pleased to welcome Bristol-Myers Squibb to the stage. My name is Carter Gould. I cover U.S. bi ...

Bristol Myers Squibb (BMY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Shares of this biopharmaceutical company have returned +7.7% over the past month versus the Zacks S&P 500 composite's +4.4% change. The Zacks Medical - Biomedical and Genetics industry, to which Bristol Myers belongs, has gained 4% over this period. Now the key question is: Where could the s ...

Bristol-Myers Squibb Company (NYSE:BMY) Leerink Partners Global Biopharma Conference 2024 Conference Transcript March 13, 2024 10:00 AM ET Executives Samit Hirawat - Executive Vice President, Chief Medical Officer, Head, Development Tim Power - Investor Relations Janet Barth - Investor Relations Analysts Dave Risinger - Leerink Partners Dave Risinger Great. So, good morning, everyone. My name is Dave Risinger. I cover diversified biopharmaceuticals for Leerink Partners and it’s very much my pleasure to welc ...